COVID-19 住院患者死亡临床预测模型:外部验证与个体参与者数据 Meta 分析
该研究采用两阶段个体参与者数据 Meta 分析,在 18 个国家 46 914 例实验室确诊 COVID-19 住院患者中外部验证 8 个预后模型。Knight 4C 死亡评分(汇总 C 统计量 0.80,95%CI 0.75 至 0.84)与 Wang 临床模型(0.77,95%CI 0.73 至 0.80)区分度最高,但观察死亡数均低于预测值,实施前需重新校准。
要点
- Knight 4C 死亡评分汇总 C 统计量 0.80(95%CI 0.75 至 0.84),区分度最高。
- Wang 临床模型汇总 C 统计量 0.77(95%CI 0.73 至 0.80)。
- 4C 评分观察死亡数平均比预测少 29%(汇总 O:E 0.71,95%CI 0.45 至 1.11)。
核心结论
- 所纳入模型的预后价值在不同数据来源之间差异很大。
- Knight 4C 死亡评分与 Wang 临床模型看起来最有前景,但在常规照护中实施前需要重新校准(更新截距与斜率)。
研究设计与样本
- 研究设计为两阶段个体参与者数据 Meta 分析,设置于二级和三级照护机构。
- 共纳入 18 个国家 27 个簇的 46 914 例患者,均为 2019 年 11 月至 2021 年 4 月因聚合酶链反应确诊 COVID-19 住院者。
- 数据来源包括巴西、比利时、中国、捷克共和国、埃及、法国、伊朗、以色列、意大利、墨西哥、荷兰、葡萄牙、俄罗斯、沙特阿拉伯、西班牙、瑞典、英国和美国的多个(聚类)队列。
- 通过 living 系统综述、PROSPERO、参考文献核查与专家知识识别预后模型,排除了参与域 PROBAST 偏倚风险高或适用性差的先验模型。
- 共识别并验证 8 个具有不同预测因子的预后模型,对模型一致性(C)统计量、校准斜率、大范围校准和观察与预期比(O:E)进行两阶段个体参与者数据 Meta 分析。
主要发现
- 汇总估计范围为 C 统计量 0.67 至 0.80、校准斜率 0.22 至 1.22、O:E 比 0.18 至 2.59,且研究间存在大量异质性。
- Knight 等 4C 死亡评分汇总 C 统计量 0.80(95%CI 0.75 至 0.84,95%预测区间 0.72 至 0.86),区分度最高。
- Wang 等临床模型汇总 C 统计量 0.77(95%CI 0.73 至 0.80,95%预测区间 0.63 至 0.87)。
- 4C 死亡评分观察死亡数平均比预测少 29%(汇总 O:E 0.71,95%CI 0.45 至 1.11,95%预测区间 0.21 至 2.39)。
- Wang 临床模型观察死亡数平均比预测少 35%(汇总 O:E 0.65,95%CI 0.52 至 0.82,95%预测区间 0.23 至 1.89);Xie 等模型观察死亡数平均比预测少 4%(汇总 O:E 0.96,95%CI 0.59 至 1.55,95%预测区间 0.21 至 4.28)。
关键数值与推荐
- 主要结局指标为 30 天死亡率或住院死亡率。
- Knight 4C 死亡评分汇总 C 统计量 0.80(95%CI 0.75 至 0.84,95%预测区间 0.72 至 0.86)。
- Wang 临床模型汇总 C 统计量 0.77(95%CI 0.73 至 0.80,95%预测区间 0.63 至 0.87)。
- 4C 死亡评分汇总 O:E 0.71(95%CI 0.45 至 1.11,95%预测区间 0.21 至 2.39)。
- Wang 临床模型汇总 O:E 0.65(95%CI 0.52 至 0.82,95%预测区间 0.23 至 1.89);Xie 等模型汇总 O:E 0.96(95%CI 0.59 至 1.55,95%预测区间 0.21 至 4.28)。
临床怎么用
- 作者认为 Knight 4C 死亡评分与 Wang 临床模型看起来最有前景,但在常规照护中实施前需要重新校准(更新截距与斜率)。
- 原文未据此给出其他临床推荐。
局限性
- 原文报告汇总估计易受研究间大量异质性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To externally validate various prognostic models and scoring rules for predicting short term mortality in patients admitted to hospital for covid-19. DESIGN: Two stage individual participant data meta-analysis. SETTING: Secondary and tertiary care. PARTICIPANTS: 46 914 patients across 18 countries, admitted to a hospital with polymerase chain reaction confirmed covid-19 from November 2019 to April 2021. DATA SOURCES: Multiple (clustered) cohorts in Brazil, Belgium, China, Czech Republic, Egypt, France, Iran, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Saudi Arabia, Spain, Sweden, United Kingdom, and United States previously identified by a living systematic review of covid-19 prediction models published in The BMJ, and through PROSPERO, reference checking, and expert knowledge. MODEL SELECTION AND ELIGIBILITY CRITERIA: Prognostic models identified by the living systematic review and through contacting experts. A priori models were excluded that had a high risk of bias in the participant domain of PROBAST (prediction model study risk of bias assessment tool) or for which the applicability was deemed poor. METHODS: Eight prognostic models with diverse predictors were identified and validated. A two stage individual participant data meta-analysis was performed of the estimated model concordance (C) statistic, calibration slope, calibration-in-the-large, and observed to expected ratio (O:E) across the included clusters. MAIN OUTCOME MEASURES: 30 day mortality or in-hospital mortality. RESULTS: Datasets included 27 clusters from 18 different countries and contained data on 46 914patients. The pooled estimates ranged from 0.67 to 0.80 (C statistic), 0.22 to 1.22 (calibration slope), and 0.18 to 2.59 (O:E ratio) and were prone to substantial between study heterogeneity. The 4C Mortality Score by Knight et al (pooled C statistic 0.80, 95% confidence interval 0.75 to 0.84, 95% prediction interval 0.72 to 0.86) and clinical model by Wang et al (0.77, 0.73 to 0.80, 0.63 to 0.87) had the highest discriminative ability. On average, 29% fewer deaths were observed than predicted by the 4C Mortality Score (pooled O:E 0.71, 95% confidence interval 0.45 to 1.11, 95% prediction interval 0.21 to 2.39), 35% fewer than predicted by the Wang clinical model (0.65, 0.52 to 0.82, 0.23 to 1.89), and 4% fewer than predicted by Xie et al's model (0.96, 0.59 to 1.55, 0.21 to 4.28). CONCLUSION: The prognostic value of the included models varied greatly between the data sources. Although the Knight 4C Mortality Score and Wang clinical model appeared most promising, recalibration (intercept and slope updates) is needed before implementation in routine care.
引用
- de Jong VMT, Rousset RZ, Antonio-Villa NE, et al. Clinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis. BMJ. 2022. PMID: 35820692. doi:10.1136/bmj-2021-069881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。